Glass House Brands (GLAS) Cash from Operations (2020 - 2026)
Glass House Brands (GLAS) posted quarterly Cash from Operations of 11755000.0 for Q1 2026, down 575.72% year-over-year from 2471000.0 in Q1 2025, and down 213.63% quarter-over-quarter from 3748000.0 in Q4 2025.
Glass House Brands (GLAS) Cash from Operations (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has reported Cash from Operations for 7 consecutive years, with 11755000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 575.72% year-over-year to 11755000.0; the TTM figure through Mar 2026 stood at 2826000.0 (down 108.63% YoY), while the FY2025 annual figure was 11400000.0, down 59.85% from the prior year.
- Cash from Operations declined to 11755000.0 in Q1 2026 per GLAS's latest filing, from 3748000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 21783228000000.0 in Q3 2023 and bottomed at 15478419000000.0 in Q4 2022.
- Historically, Cash from Operations has averaged 370875395647.06 across 5 years, with a median of 7270000.0 in 2022.
- Annual changes were most pronounced in 2023 — Cash from Operations surged 299631646.91% — and 2026, when it tumbled 575.72%.
- Glass House Brands' Cash from Operations stood at 15478419000000.0 in 2022, then jumped by 100.0% to 1441000.0 in 2023, then soared by 468.49% to 8192000.0 in 2024, then slumped by 145.75% to 3748000.0 in 2025, then tumbled by 213.63% to 11755000.0 in 2026.
- Business Quant data shows GLAS's Cash from Operations at 11755000.0 in Q1 2026, 3748000.0 in Q4 2025, and 5060000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Glass House Brands | 831.09 Mn | 812.54 Mn | 15.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -11.76 Mn |
| Mar 31, 2026 | -11.76 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Dec 31, 2025 | -3.75 Mn |
| Sep 30, 2025 | -5.06 Mn |
| Sep 30, 2025 | -5.06 Mn |
| Jun 30, 2025 | 17.74 Mn |
| Jun 30, 2025 | 17.74 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Mar 31, 2025 | 2.47 Mn |
| Dec 31, 2024 | 8.19 Mn |
| Dec 31, 2024 | 8.19 Mn |
| Sep 30, 2024 | 13.18 Mn |
| Sep 30, 2024 | 13.18 Mn |
| Jun 30, 2024 | 8.90 Mn |
| Jun 30, 2024 | 8.90 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Mar 31, 2024 | -1.88 Mn |
| Dec 31, 2023 | 1.44 Mn |
| Dec 31, 2023 | 1.44 Mn |